<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01127048</url>
  </required_header>
  <id_info>
    <org_study_id>EA-08-1-34</org_study_id>
    <nct_id>NCT01127048</nct_id>
  </id_info>
  <brief_title>Prospan® Hustenzäpfchen - Investigation on Efficacy and Tolerability in Children</brief_title>
  <official_title>Investigation on Efficacy and Tolerability of Prospan® Hustenzäpfchen for the Symptomatic Treatment of Acute Bronchitis Accompanied by Coughing in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Engelhard Arzneimittel GmbH &amp; Co.KG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Engelhard Arzneimittel GmbH &amp; Co.KG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aims of this study are&#xD;
&#xD;
        -  Demonstrating superior efficacy of Prospan® Hustenzäpfchen compared to Placebo in&#xD;
           children suffering from acute bronchitis accompanied by coughing&#xD;
&#xD;
        -  Characterisation of safety and tolerability of Prospan® Hustenzäpfchen in comparison&#xD;
           with placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After interim analysis of the first part the clinical study will be continued as follows:&#xD;
      Double blind, placebo controlled, randomised, multi-centre study with 2-parallel groups for&#xD;
      the treatment of acute bronchitis accompanied by coughing in children aged 0 - 6 years to&#xD;
      demonstrate efficacy and safety of Prospan® Hustenzäpfchen.&#xD;
&#xD;
      For assessment of cough intensity and severity a specific symptom score has been developed,&#xD;
      which gathers the child's frequency and severity of coughing and of cough productivity as&#xD;
      well as the severity of rhonchi (each symptom will be assessed on a four-point Likert scale&#xD;
      ranging from 0 to 3; total score range: 0-12 points).&#xD;
&#xD;
      Considering the specificities of the study population and the disease, confirmatory&#xD;
      evaluation will be based on the change in the symptom score after the first three consecutive&#xD;
      days of treatment as assessed by the investigator.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2008</start_date>
  <completion_date type="Anticipated">August 2013</completion_date>
  <primary_completion_date type="Anticipated">August 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary outcome measure</measure>
    <time_frame>7 days</time_frame>
    <description>Effect of treatment as primary variable will be assessed by comparing baseline values to those obtained during visit 2.&#xD;
The primary outcome measure for efficacy will be the relative change in the symptom score between visits 1 and 2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary variables</measure>
    <time_frame>7 days</time_frame>
    <description>absolute change of total symptom score&#xD;
time to response&#xD;
compliance, defined by drug accountability&#xD;
percentage of patients requiring concomitant medication for treatment of cough&#xD;
rates of premature withdrawal&#xD;
incidence of Adverse Events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1400</enrollment>
  <condition>Symptoms of Acute Bronchitis Accompanied by Coughing</condition>
  <arm_group>
    <arm_group_label>Prospan Hustenzäpfchen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Suppositories containing Ivy leaves dry extract</intervention_name>
    <description>Suppositories containing Ivy leaves dry extract</description>
    <arm_group_label>Prospan Hustenzäpfchen</arm_group_label>
    <other_name>Prospan® Hustenzäpfchen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Suppositories containing no Ivy leaves dry extract</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. male or female children aged 0 to 6 years&#xD;
&#xD;
          2. acute bronchitis existing not longer than three days and accompanied by coughing&#xD;
&#xD;
          3. symptom rating score of ≥ 5 assessed by the investigator&#xD;
&#xD;
          4. symptom 'frequency of coughing' of ≥ 2 assessed by the investigator&#xD;
&#xD;
          5. the patient's legal representatives must give informed consent in accordance with the&#xD;
             supposed will of the patient, after having been informed about benefits and potential&#xD;
             risks of the trial, as well as details of the insurance taken out to cover the risk&#xD;
             for patients participating in the study -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. hypersensitivity to the active ingredient or to any further constituents of the&#xD;
             pharmaceutical preparations&#xD;
&#xD;
          2. patients with severe allergies or multiple drug allergies&#xD;
&#xD;
          3. any other pulmonary disease within the last two weeks&#xD;
&#xD;
          4. chronic pulmonary diseases&#xD;
&#xD;
          5. exacerbation of chronic pulmonary disease&#xD;
&#xD;
          6. suspicion of bacterial pulmonary infection&#xD;
&#xD;
          7. fever above 39°C (rectal measurement) -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerhard Zwacka, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_contact>
    <last_name>Manuela Stauss-Grabo, Dr.</last_name>
    <email>m.stauss-grabo@engelhard-am.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Engelhard Arzneimittel GmbH &amp; Co. KG</name>
      <address>
        <city>Niederdorfelden</city>
        <zip>61138</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuela Stauss-Grabo, Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <study_first_submitted>May 3, 2010</study_first_submitted>
  <study_first_submitted_qc>May 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2010</study_first_posted>
  <last_update_submitted>June 14, 2011</last_update_submitted>
  <last_update_submitted_qc>June 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 15, 2011</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. Gerhard Zwacka</name_title>
    <organization>Robert-Koch-Krankenhaus Apolda</organization>
  </responsible_party>
  <keyword>bronchitis</keyword>
  <keyword>coughing</keyword>
  <keyword>children</keyword>
  <keyword>Ivy</keyword>
  <keyword>Hedera helix L.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchitis</mesh_term>
    <mesh_term>Cough</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

